Jubilant DraxImage receives approval from Health Canada for the RUBY Elution System™ (RbES) and proprietary RUBY™ Consumable Accessories
13 oct. 2017 11h29 HE
|
Jubilant DraxImage
Montreal, QC, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma whollyowned subsidiary, is pleased to announce it has received approval from Health Canada...
Chelsea Therapeutics to Present At the Rodman and Renshaw 10th Annual Healthcare Conference On Monday, November 10, 2008
30 oct. 2008 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference at 3:40...
Chelsea Therapeutics to Present At the UBS Global Life Sciences Conference On Monday, September 22, 2008
16 sept. 2008 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 16, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the UBS Global Life Sciences Conference at 11:00 AM on Monday,...
Antisoma Announces Promising Preliminary Phase II Data for AS1404 in Lung Cancer
17 oct. 2005 02h19 HE
|
Antisoma plc
LONDON, Oct. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. With initial data...
Crucell Announces Evaluation by Genentech of STAR(TM) Technology
07 janv. 2005 02h08 HE
|
Crucell N.V.
LEIDEN, The Netherlands, Jan. 7, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that Genentech, Inc. (NYSE:DNA) is currently evaluating...